[News Brief] Innovent Biologics and Pfizer Sign Oncology Collaboration
China-based Innovent Biologics and Pfizer have entered a global licensing and collaboration agreement to research and develop twelve early-stage cancer…
Global PR
[News Brief] Everest Medicines Licenses Kidney Disease Therapy to Travere
China-based Everest Medicines has entered an exclusive licensing and collaboration agreement with US-based Travere Therapeutics for the development and commercialisation…
[News Brief] FDA Approves Tremfya Label Expansion for Psoriatic Arthritis
The US Food and Drug Administration (FDA) has approved a label expansion for Tremfya (guselkumab) to include evidence for inhibition…
[News Brief] Pfizer Receives FDA Approval for Expanded Hympavzi Use
Pfizer has received US Food and Drug Administration (FDA) approval for an expanded indication of Hympavzi (marstacimab-hncq) for adults and…
[News Brief] Everest Medicines Licences Sumecigrel for Asia-Pacific Development
Everest Medicines has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co. for the development, registration and commercialisation…
[News Brief] Simcere Pharma Enters Research Collaboration With Stanford Medicine
Simcere Pharmaceutical Group Limited has entered a research collaboration with Stanford University School of Medicine to develop potential treatments for…
[News Brief] Zhenjiankang Medical Passes Hong Kong Listing Hearing
Guangdong Zhenjiankang Medical Technology Development Co., Ltd. has passed the Hong Kong Stock Exchange Main Board listing hearing under Chapter…
[News Brief] Metis TechBio Raises HK$2.1 Billion Through Hong Kong IPO
Metis TechBio Co Ltd has completed an initial public offering in Hong Kong, raising more than HK$2.1 billion to support…
[News Brief] MicroPort CardioFlow Launches LBBOT Solution in Europe, Australia
MicroPort CardioFlow has announced the commercial launch of its LBBOT Solution in Europe and Australia following applicable regulatory clearances, introducing…
[News Brief] Legend Biotech to Present LB2501 Data at EHA 2026
Legend Biotech Corporation has announced that it will present preliminary Phase 1 clinical data for its investigational LB2501 therapy during…